Clinical Trials Logo

Clinical Trial Summary

Investigate the nephroprotective effect of Activated Charcoal and Probiotic in limiting the progression of renal impairment in patients with chronic kidney disease and improving of renal function test and phosphate level. Condition or disease: chronic kidney disease


Clinical Trial Description

Chronic kidney disease (CKD) is characterized by a gradual decrease in the glomerular filtration rate (GFR) and proteinuria. CKD is a global health problem, and its incidence has been increasing. The estimated global prevalence of CKD is 8-14%. When kidney function deteriorates gradually, many metabolites accumulate in the body. These accumulated substances, termed as uremic toxins (UTs), can result in adverse pathophysiological outcomes. UTs can affect multiple organs and cause renal fibrosis, vascular calcification, anemia, peripheral arterial disease, adynamic bone disease, adipocyte dysfunction with insulin resistance, impaired immune system, and uremic pruritus. The pathophysiological mechanisms through which UTs cause multiple organ damage are complex and not completely understood. These mechanisms may include inflammation, reactive oxidative stress, cellular transdifferentiation, impaired mitochondria function, intestinal barrier destruction, and changes in intestinal microbiota. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05540431
Study type Interventional
Source Kufa University
Contact Waleed Khaild Rahman, Bachelor of pharmacy
Phone +9647809763160
Email ph.waleedkhaild99@gmail.com
Status Not yet recruiting
Phase Phase 2/Phase 3
Start date September 25, 2022
Completion date December 20, 2023